[Form 3] Waldencast plc Initial Statement of Beneficial Ownership
This article details the initial statement of beneficial ownership filed by Juliette Hickman, a director at Waldencast plc. She holds 80,952 Class A ordinary shares directly and 18,727 restricted stock units (RSUs) which represent contingent rights to Class A ordinary shares. The RSUs vest in tranches, with the final portion vesting on October 28, 2026.
Waldencast plc (WALD) director reports direct and indirect share stakes
Waldencast plc director Thompson Motta Roberto Moses filed an initial ownership report (Form 3) detailing his stake in the company's Class A Ordinary Shares. The filing indicates he holds 18,727 shares directly and 100,000 indirectly through Nexus Limited, controlled by his spouse, for which he disclaims beneficial ownership except for his pecuniary interest. This report establishes his initial insider ownership and does not reflect new purchases or sales.
Waldencast (WALD) CEO Michel Brousset reports options, RSUs and indirect stakes
Waldencast plc CEO Michel Brousset has filed an initial statement detailing his equity holdings in the company, as per a Form 3 SEC filing. His holdings include direct stock options for over 4.1 million Class A ordinary shares, 264,294 restricted stock units (RSUs), and 952,865 directly owned Class A ordinary shares. Additionally, he has indirect beneficial ownership through Waldencast Ventures LP, which accounts for millions more Class A ordinary shares and shares issuable from warrants.
Waldencast (WALD) director details large indirect share, warrant and option holdings
Waldencast plc director Cristiano Souza has disclosed significant indirect and derivative stakes in the company through an initial statement of ownership (Form 3). He is the controlling shareholder of Zeno Equity Partners LLP, which holds over 12 million Class A ordinary shares and warrants for nearly 5 million more. Additionally, Souza holds stock options for 712,083 Class A shares and a put option that could grant him further equity.
Waldencast (WALD) director lists 37,454 Class A Ordinary Shares
Waldencast plc director Brookie Kelly has filed an initial ownership report (Form 3) disclosing a direct holding of 37,454 Class A Ordinary Shares. This filing establishes Kelly's current equity position and does not indicate any recent purchase or sale activity. The report confirms Kelly's role as a director and outlines the details of the beneficially owned non-derivative securities.
Waldencast (WALD) director details initial share and RSU holdings
Waldencast director Aaron Chatterley filed an initial ownership report (Form 3) detailing his equity stake in the company. He reported direct ownership of 57,453 Class A ordinary shares and restricted stock units (RSUs) tied to 18,727 underlying Class A ordinary shares. The RSUs, totaling 56,180, were granted on February 12, 2025, and vest in three tranches, with each RSU representing a contingent right to receive one Class A ordinary share or an equivalent cash amount.
Waldencast (WALD) executive Hind Sebti details options, RSUs and shares
Waldencast plc (WALD) Chief Growth Officer Hind Sebti has reported her equity holdings in the company via an SEC Form 3 filing. She holds 507,434 Class A ordinary shares directly, stock options for 1,594,660 Class A ordinary shares at an exercise price of $3.98, and 193,816 restricted stock units. These options and RSUs have specific vesting schedules extending through 2028 and 2027, respectively, illustrating her present and future equity-based compensation from the company.
Canaccord cuts Waldencast stock price target on elevated costs
Canaccord has lowered its price target for Waldencast (NASDAQ: WALD) stock to $2.00 from $4.00, maintaining a Buy rating, due to elevated costs associated with an SEC investigation and strategic review. The company recently reported mixed Q4 and fiscal year 2025 results, with an impressive gross profit margin despite not being profitable in the last twelve months. Waldencast continues to address the SEC inquiry while its subsidiary, Obagi Medical, expands its presence through new partnerships for its injectable filler.
Waldencast (WALD) Trailing US$229.7 Million Loss Reinforces Bearish Profitability Narratives
Waldencast (WALD) has reported a significant trailing twelve-month net loss of US$229.7 million, widening from previous periods, despite revenue of US$272.1 million. This reinforces bearish arguments about the company's profitability, as losses have increased year-over-year and analysts do not forecast profitability within the next three years. While some bullish investors point to potential revenue growth and future margin recovery, the current financial performance and mixed valuation signals highlight a challenging path to breakeven.
Big impairments and control risks at Waldencast (Nasdaq: WALD) in 2025 filing
Waldencast plc's 2025 annual report highlights significant financial and operational challenges, including substantial non-cash impairment charges of $132.1 million for Obagi Medical and $20.0 million for Milk Makeup, comprising 81% of total assets. The company also faces heightened financial risks due to its Lumina Credit Agreement, which includes restrictive covenants and potential shareholder dilution from warrants, alongside ongoing material weaknesses in internal control over financial reporting and an SEC investigation related to prior restatements. These issues increase regulatory and execution risks, making future performance and shareholder value uncertain.
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
Waldencast plc (NASDAQ: WALD) has announced that its Fourth Quarter and Fiscal Year 2025 earnings will be released via press release on March 13, 2026, before the U.S. market opens. The company will not be holding a conference call due to its ongoing strategic review. Waldencast, a global multi-brand beauty and wellness platform, aims to build a leading operating platform through developing, acquiring, accelerating, and scaling "conscious, high-growth purpose-driven brands."
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
Waldencast plc (NASDAQ: WALD), a global beauty and wellness platform, announced it will release its Fourth Quarter and Fiscal Year 2025 earnings on March 13, 2026, before the U.S. market opens. The company does not plan to host a conference call due to its ongoing strategic review. Waldencast aims to build a leading operating platform by acquiring and scaling conscious, high-growth, purpose-driven brands, already including Obagi Medical and Milk Makeup.
Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
Obagi Medical has launched a new Lip Therapy protocol featuring two innovative products: the AHA + PHA Smoothing Micro-Peel and the Soothe & Protect Lip Treatment SPF 30. This two-step regimen aims to gently resurface, hydrate, and protect the delicate skin on the lips, addressing concerns like texture, fine lines, and environmental damage. The dermatologist-tested duo is designed for nightly rejuvenation and daily protection, providing visible smoothing and improved lip health.
Obagi Medical Launches ALOHA Program to Drive Innovation in Aesthetic Solutions and Introduce First FDA-Approved Injectable Hyaluronic Acid Filler
Obagi Medical has launched the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, aimed at driving innovation in aesthetic solutions and supporting the introduction of its first FDA-approved injectable hyaluronic acid filler, Obagi® saypha® MagIQ™. This program will gather real-world data from practitioners using the new filler, facilitating a deeper understanding of its effectiveness and contributing to practice success and patient satisfaction. Obagi® saypha® MagIQ™ is highlighted for its high usable HA content and consistent application characteristics, marking a significant step for Obagi Medical in the aesthetic market.
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc's stock has dropped 30% in the last month, contributing to a 49% decline over the past year. Despite this, the company's price-to-sales (P/S) ratio of 0.6x is similar to the Personal Products industry median of 0.8x. Analysts expect Waldencast's revenue growth of 4.6% next year to closely track the industry's 5.2% growth, suggesting that investors are comfortable with the current valuation and do not foresee significant changes in the near future.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. This investigation follows Waldencast's revised financial outlook for 2025, which significantly lowered previous guidance for net revenue growth and adjusted EBITDA, coupled with reported net losses driven by substantial impairment charges on its Obagi Medical and Milk Makeup brands. Following this news, Waldencast's share price dropped by 6.49%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Waldencast's announcement of a revised financial outlook for 2025, significantly lowering revenue growth and EBITDA margin expectations, and reporting a net loss driven by impairment charges on its Obagi Medical and Milk Makeup brands, which caused a drop in share price. Investors impacted are encouraged to contact the firm regarding joining a potential class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Waldencast's revised financial outlook for 2025, which significantly lowered previous growth and EBITDA margin guidance. The company also reported substantial impairment charges on its Obagi Medical and Milk Makeup brands, leading to a 6.49% drop in share price on November 24, 2025.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of its investors. This investigation follows Waldencast's revised 2025 financial outlook, which projected significantly lower revenue growth and EBITDA margins than previously guided, alongside a reported net loss driven by substantial impairment charges. The news led to a 6.49% drop in Waldencast's Class A ordinary share price.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ:WALD) after a significant drop in its stock price. This follows Waldencast's revised financial outlook for 2025, which downgraded projected net revenue growth and adjusted EBITDA margin, and reported a substantial net loss due to impairment charges on its Obagi Medical and Milk Makeup brands. Investors are encouraged to contact Pomerantz LLP regarding their legal options.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Waldencast plc (WALD) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Waldencast plc (NASDAQ:WALD) following the company's Q2 2025 financial results. Waldencast updated its full-year 2025 financial outlook, forecasting net revenue broadly in line with 2024 and an adjusted EBITDA margin in the high single digits, a significant reduction from previous guidance. The company also reported a net loss of $185.2 million for H1 2025, driven by impairment charges on its Obagi Medical and Milk Makeup brands, which led to a 6.49% drop in its Class A ordinary share price.
Waldencast plc (WALD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Waldencast plc (NASDAQ:WALD) following a significant drop in its Class A ordinary share price. This decline occurred after the company updated its 2025 financial outlook, projecting lower revenue growth and EBITDA margins than previously guided, and reported substantial net losses due to impairment charges on its brands. Investors who purchased Waldencast securities are encouraged to contact the firm for more information regarding the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. This investigation follows the company's updated financial outlook for 2025, which significantly lowered previous expectations for net revenue growth and adjusted EBITDA margin. The financial update also revealed a substantial net loss for the first half of 2025, driven by significant impairment charges on its Obagi Medical and Milk Makeup brands, leading to a drop in Waldencast's share price.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Waldencast plc (WALD) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. This investigation follows Waldencast's revised 2025 financial outlook, which significantly reduced revenue growth and EBITDA margin expectations, along with reported net losses and impairment charges for its Obagi Medical and Milk Makeup brands. The firm encourages affected investors to contact them to assist in the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. This investigation follows a significant drop in Waldencast's share price after the company updated its financial outlook for 2025, lowering revenue growth and EBITDA margin expectations, and reported substantial impairment charges for its Obagi Medical and Milk Makeup brands. Investors who believe they have been affected are encouraged to contact the law firm for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages Waldencast plc (WALD) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Waldencast plc (NASDAQ:WALD) stockholders following a significant drop in share price. This investigation stems from Waldencast's revised financial outlook for 2025, which included sharply lowered revenue growth and EBITDA margin expectations, alongside substantial impairment charges on its Obagi Medical and Milk Makeup brands. The firm is encouraging affected investors to inquire about the securities investigation.
Waldencast plc (WALD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Waldencast plc (NASDAQ:WALD) after the company updated its financial outlook for 2025, significantly lowering its revenue growth and EBITDA margin expectations. This update, along with reported impairment charges on its Obagi Medical and Milk Makeup brands, led to a drop in Waldencast's share price. The firm is encouraging stockholders to contact them to learn more about the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) on behalf of investors. The investigation follows Waldencast's revised financial outlook for 2025, which indicated significantly lower revenue and adjusted EBITDA margin expectations compared to previous guidance, alongside substantial impairment charges on their Obagi Medical and Milk Makeup brands. This news led to an immediate drop in Waldencast's share price.
Waldencast schedules annual meeting and announces board changes By Investing.com
Waldencast plc announced its 2025 annual general meeting for January 14, 2026, where shareholders will vote on renewing Class III directors. The company also reported board changes, including the resignations of Lindsay Pattison and Zack Werner, and reclassified its remaining directors into three classes. These announcements come after recent disappointing sales results and revised price targets from analysts.
Waldencast schedules annual meeting and announces board changes
Waldencast plc announced its 2025 annual general meeting of shareholders will be held on January 14, 2026, in London, with a record date of December 9, 2025, for voting eligibility. The company also disclosed board changes, with Lindsay Pattison and Zack Werner resigning, and a reclassification of directors into three classes, with shareholders voting on Class III re-appointments. These announcements come after Waldencast reported disappointing second and third-quarter sales results, leading to adjusted price targets from analysts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) following a significant drop in its share price. This comes after the company updated its 2025 financial outlook, projecting lower revenue growth and adjusted EBITDA margins than previously guided, alongside reporting a net loss driven by substantial impairment charges. Investors are advised to contact Pomerantz LLP for information regarding a potential class action lawsuit.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Waldencast plc (WALD) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Waldencast plc (NASDAQ: WALD) following a significant drop in its Class A ordinary share price. This move comes after Waldencast updated its financial outlook for 2025, lowering revenue growth and EBITDA margin guidance and reporting a substantial net loss with impairment charges on its Obagi Medical and Milk Makeup brands. The firm is encouraging investors who purchased Waldencast securities to join the investigation to potentially recover losses.
Bronstein, Gewirtz & Grossman, LLC Encourages Waldencast plc (WALD) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Waldencast plc (NASDAQ: WALD) after the company updated its financial outlook for 2025, expecting lower net revenue growth and adjusted EBITDA margin than previously guided. The company also reported a net loss of $185.2 million for the first half of 2025, largely due to significant impairment charges on its Obagi Medical and Milk Makeup brands, causing its share price to drop. Investors are encouraged to contact the firm for more information regarding this securities investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors regarding potential securities fraud and unlawful business practices. This investigation follows Waldencast's updated full-year 2025 financial outlook, which projected net revenue in line with 2024 and a lower adjusted EBITDA margin, as well as a significant net loss partly due to impairment charges on their Obagi Medical and Milk Makeup brands. The announcement led to a 6.49% drop in Waldencast's Class A ordinary share price.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Waldencast's updated financial outlook for 2025, which projected net revenue broadly in line with 2024 and adjusted EBITDA in the high single digits, significantly lower than previous guidance, and a reported net loss of $185.2 million with impairment charges. Consequently, Waldencast's share price dropped by 6.49%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Waldencast's revised financial outlook for 2025, which included lower revenue growth and EBITDA margin guidance, and reported a significant net loss driven by impairment charges on its Obagi Medical and Milk Makeup brands. The announcement led to a 6.49% drop in Waldencast's share price.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Waldencast's revised 2025 financial outlook, which downgraded revenue growth and EBITDA margin expectations and reported a significant net loss driven by impairment charges on its Obagi Medical and Milk Makeup brands, leading to a stock price drop. Investors are encouraged to contact Pomerantz LLP to inquire about joining a potential class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc (NASDAQ: WALD) following a significant drop in its share price. The investigation comes after Waldencast updated its financial outlook for 2025, lowering revenue growth and EBITDA margin expectations, and reporting a substantial net loss driven by impairment charges on its Obagi Medical and Milk Makeup brands. The firm advises affected investors to contact them regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD
Pomerantz LLP is investigating Waldencast plc (NASDAQ: WALD) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows Waldencast's revised 2025 financial outlook, which downgraded revenue growth expectations and adjusted EBITDA margin, and reported significant impairment charges on its Obagi Medical and Milk Makeup brands, leading to a stock price drop. Investors are encouraged to contact Pomerantz LLP to inquire about joining the class action.
Waldencast Expands U.S. Market Presence with Novaestiq Acquisition
Waldencast plc has acquired Novaestiq Corp., securing exclusive U.S. rights to commercialize Saypha® dermal fillers and expanding into the high-growth injectable dermal filler market. Following FDA approval for Saypha® MagIQ™, Waldencast issued shares as part of the agreement and amended its credit agreement for financial flexibility. While the acquisition shows strategic growth and strong technical momentum, Waldencast faces ongoing profitability and cash flow challenges, making its valuation metrics unattractive.
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc (NASDAQ:WALD) shares have risen 33% in the last month, though they are still down 22% over the last year. Despite the recent jump, its price-to-sales (P/S) ratio of 1.1x is similar to the industry median, indicating that investors might be overlooking specific factors. The company's recent revenue growth has been positive compared to declining industry trends, with analysts forecasting a 4.6% increase in revenue for the coming year, aligning its P/S ratio with industry peers.
Dow Jumps 300 Points; Waldencast Shares Plunge
U.S. stocks saw broad gains, with the Nasdaq Composite up over 500 points and the Dow rising 0.65%. This positive market movement occurred despite a decline in the Dallas Fed's general business activity index for Texas manufacturing. Several individual stocks experienced significant movements, including Enlivex Therapeutics and Inno Holdings soaring upwards, while Waldencast plc and Twin Hospitality Group saw declines.
Waldencast Reports Mixed Q2 and Q3 2025 Financial Performance; Highlights Growth in Obagi Medical and Challenges for Milk Makeup
Waldencast plc (NASDAQ: WALD) reported mixed financial results for Q2 and Q3 2025, with strong performance in Obagi Medical, driven by e-commerce and international markets, but a decline in Milk Makeup's international sales despite U.S. growth. The company is pursuing strategic initiatives, including expanding into medical aesthetics with the Novaestiq acquisition and strengthening its balance sheet through the sale of Obagi Japan trademark rights. Waldencast has updated its full-year 2025 guidance, expecting revenue to be in line with 2024 and Adjusted EBITDA Margin in the high single digits, while continuing a strategic review to maximize shareholder value.
Waldencast Reports Mixed Q2 and Q3 2025 Financial Performance; Highlights Growth in Obagi Medical and Challenges for Milk Makeup
Waldencast plc reported mixed financial results for Q2 and Q3 2025, with Obagi Medical achieving strong double-digit growth driven by e-commerce and international markets, while Milk Makeup faced a decline in international sales despite U.S. growth. The company is advancing strategic initiatives in medical aesthetics and has strengthened its balance sheet after selling the Obagi Japan trademark. Despite an overall stable year-to-date revenue, adjusted EBITDA margin decreased, leading to updated fiscal year projections and an ongoing strategic review to maximize shareholder value.
Waldencast plc Sells Obagi Trademark Rights in Japan to Rohto Pharmaceutical for $82.5 Million
Waldencast plc announced the sale of its "Obagi" trademark rights in Japan to Rohto Pharmaceutical Co., Ltd. for $82.5 million, a strategic move to strengthen its balance sheet. This comes after Rohto successfully licensed the brand since 2002 without overlap with the global Obagi Medical brand. Concurrently, Waldencast secured a new $225 million credit agreement with Lumina Capital Management to enhance liquidity, with a significant portion of the trademark sale proceeds intended to repay this new loan and maximize shareholder value.
Waldencast PLC (NASDAQ:WALD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Waldencast PLC (NASDAQ:WALD) has received a consensus rating of "Moderate Buy" from analysts, with an average one-year price target of $4.9714. The company's stock recently traded up 1.1%, and institutional investors have been adjusting their positions. Waldencast operates in the beauty and wellness business, developing and acquiring various brands including Obagi Medical.
Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum
Obagi Medical has introduced Nu-Cil® BioStim™ Scalp Serum, a new product designed to promote fuller, denser-looking hair and a healthier scalp. The serum, which leverages Obagi's 35 years of skin health expertise, is clinically proven to reduce dry, fallen hair by 74% in three months. The launch addresses growing concerns about hair loss and thinning, with the product available for purchase on Obagi.com.
Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Croma-Pharma GmbH announced the acquisition of Novaestiq Corp. by Waldencast plc, a move that will bring Saypha injectable hyaluronic acid gels to the U.S. market under the Obagi Medical brand. This strategic milestone is part of Croma-Pharma's international growth strategy, expanding the global reach of its science-driven aesthetic solutions. The Saypha products are currently undergoing the FDA approval process, supported by robust clinical studies.
Waldencast plc acquired Novaestiq Corp. from Nvq Investors Holding, Llc and CROMA-PHARMA GmbH for $26.9 million.
Waldencast plc completed the acquisition of Novaestiq Corp. from Nvq Investors Holding, Llc and CROMA-PHARMA GmbH for $26.9 million on July 22, 2025. The transaction involved an initial cash payment of $3 million, with additional consideration based on ongoing royalties and contingent issuance of Waldencast Class A shares tied to FDA approval and revenue milestones for Saypha® products. Legal and financial advisors for both parties were also detailed.
WaterWorld - Gore Range Capital Announces Sale of Novaestiq Corp. to Waldencast
Gore Range Capital (GRC) has announced that Waldencast plc will acquire Novaestiq Corp., a GRC Fund II portfolio company. Novaestiq, a joint venture with Croma-Pharma GmbH, develops injectable hyaluronic acid gels for the US market, which Waldencast will launch under its Obagi Medical brand. This acquisition is expected to strengthen Obagi Medical's product portfolio with scientifically backed injectable solutions, marking a significant milestone for GRC and Novaestiq.
